Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development ProgramsGlobeNewsWire • 10/20/26
Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety DisorderGlobeNewsWire • 09/24/26
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderGlobeNewsWire • 09/22/26
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate UpdateGlobeNewsWire • 08/14/26
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety DisorderGlobeNewsWire • 08/06/26
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder TranscriptSeeking Alpha • 06/30/26
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety DisorderBusiness Wire • 06/30/26
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate UpdateBusiness Wire • 06/15/26
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety DisorderBusiness Wire • 06/09/26
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmPRNewsWire • 06/01/26
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/14/26
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderBusiness Wire • 05/12/26
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety DisorderBusiness Wire • 05/08/26
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock DropPRNewsWire • 04/28/26
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to MenopauseBusiness Wire • 04/22/26
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGNGlobeNewsWire • 03/17/26
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewsWire • 03/16/26
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline TonightBusiness Wire • 03/16/26